Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Period

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,142 result(s) found for: Period. Displaying page 9 of 708.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2019-002101-21 Sponsor Protocol Number: ARGX-113-1803 Start Date*: 2020-05-25
    Sponsor Name:argenx BV
    Full Title: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia
    Medical condition: Primary immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) HU (Trial now transitioned) FR (Completed) BE (Completed) CZ (Trial now transitioned) BG (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013758-33 Sponsor Protocol Number: RA0028 Start Date*: 2010-06-17
    Sponsor Name:UCB Pharma S.A.
    Full Title: MULTICENTER STUDY WITH A 16-WEEK DOUBLE-BLIND, PLACEBO-CONTROLLED (DURING THE INITIAL 2 WEEKS) RANDOMIZED PERIOD, FOLLOWED BY A 24-WEEK OPEN LABEL EXTENSION TO ASSESS MAGNETIC RESONANCE IMAGE-VERIF...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001463-39 Sponsor Protocol Number: E2006-G000-303 Start Date*: 2017-04-04
    Sponsor Name:Eisai Ltd.
    Full Title: A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel-Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder
    Medical condition: Treatment for insomnia disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10078083 Insomnia disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-001985-16 Sponsor Protocol Number: D3820C00006 Start Date*: 2011-09-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Relieving Opioid-Induced Constipation (OIC) in Patients with Cancer-Related Pain.
    Medical condition: Scientific Terminology Opioid-Induced Constipation (OIC) Laymen Terminology Constipation after taking Opioid drugs
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10071128 Opioid induced constipation LLT
    14.0 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) ES (Completed) BE (Completed) GB (Completed) CZ (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006170-28 Sponsor Protocol Number: E2007-G000-307 Start Date*: 2008-09-15
    Sponsor Name:Eisai Ltd
    Full Title: An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy i...
    Medical condition: Epilepsy: refractory partial seizures with or without secondary generalisation
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) AT (Completed) BE (Completed) PT (Completed) LT (Completed) NL (Completed) HU (Completed) FR (Completed) GB (Completed) SE (Completed) EE (Completed) LV (Completed) DK (Completed) IT (Completed) DE (Completed) FI (Completed) BG (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004237-32 Sponsor Protocol Number: 70033093THR2001 Start Date*: 2019-08-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in ...
    Medical condition: Thromboembolism in subjects who have undergone an elective primary unilateral total knee replacement
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) PL (Completed) PT (Completed) BG (Completed) ES (Completed) GR (Completed) LT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004156-19 Sponsor Protocol Number: VX11-765-402 Start Date*: 2012-06-21
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment Resistant Partial Epilepsy With...
    Medical condition: Partial epilepsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Prematurely Ended) HU (Completed) GB (Prematurely Ended) FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-004397-42 Sponsor Protocol Number: N01199 Start Date*: 2018-01-31
    Sponsor Name:UCB Pharma Inc.
    Full Title: An open-label, multi-center, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in subjects ...
    Medical condition: Epilepsy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003249-34 Sponsor Protocol Number: F13640GE209 Start Date*: 2007-09-24
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Proof of Concept study of the efficacy and tolerability of a 4-week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed. A prospective, multinationa...
    Medical condition: Patients who have failed adaptation of opioid therapy for cancer pain
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058019 Cancer pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004794-33 Sponsor Protocol Number: PA101B-UP-02 Start Date*: 2016-03-25
    Sponsor Name:Patara Pharma, LLC
    Full Title: Treatment of Uremic Pruritus with Inhaled PA101B in Patients with End-Stage Renal Disease Requiring Hemodialysis
    Medical condition: Uremic Pruritus in patients with end-stage renal disease requiring hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10060884 Uremic pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002802-48 Sponsor Protocol Number: ML 18107 Start Date*: 2006-09-22
    Sponsor Name:ROCHE
    Full Title: Evaluation of efficacy and safety of i.v. and oral ibandronate in elderly patients with bone metastases from solid tumors. A randomised phase II study
    Medical condition: Treatment of bone metastases in elderly patients with solid tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027484 Metastatic pain LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004307-30 Sponsor Protocol Number: IXA-CSP-001 Start Date*: 2017-03-30
    Sponsor Name:IXALTIS
    Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BI...
    Medical condition: Mixed Urinary Incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003609-24 Sponsor Protocol Number: CLOU064D12201 Start Date*: 2019-10-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject- and investigator-blinded, placebo controlled study to assess the efficacy and safety of LOU064 in patients with inadequately controlled asthma
    Medical condition: Inadequately controlled asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003734-17 Sponsor Protocol Number: E2007-J000-342 Start Date*: 2019-11-22
    Sponsor Name:Eisai Co., Ltd. (Japan)
    Full Title: A Multicenter, Uncontrolled, Open-label Study and Extension Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Patients with Partial Onset Seizures (Including Sec...
    Medical condition: Epilepsy : 1) Partial-Onset Seizures (POS)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000171-41 Sponsor Protocol Number: 0000726 Start Date*: Information not available in EudraCT
    Sponsor Name:Altus Pharmaceuticals Inc
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insuff...
    Medical condition: Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011766 Cystic fibrosis pancreatic LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) IT (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002275-33 Sponsor Protocol Number: 0805-2012-1 Start Date*: 2014-01-15
    Sponsor Name:Dept. of Gastroenterology, Universityhospital Odense
    Full Title: Renal and cardiac effects of terlipressin and dobutamin in cirrhosis and ascites. A randomised study.
    Medical condition: Liver cirrhosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001090-16 Sponsor Protocol Number: 2017003001 Start Date*: 2017-09-22
    Sponsor Name:University Medical Center Groningen
    Full Title: A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial
    Medical condition: Chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001571-39 Sponsor Protocol Number: 1260 Start Date*: 2011-10-31
    Sponsor Name:University of Bristol
    Full Title: Investigating the relationship between sleep disturbance and learning in children with Benign Epilepsy of Childhood with Centrotemporal Spikes (BECCTS): A Randomised Double-Blind Placebo-Controlled...
    Medical condition: Benign Epilepsy of Childhood with Centrotemporal Spikes (BECCTS). (Also known as Benign Rolandic Epilepsy.)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10070530 Benign rolandic epilepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023802-10 Sponsor Protocol Number: B1801023 Start Date*: 2011-07-29
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELATED ARTHRITIS, OR P...
    Medical condition: OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Completed) LT (Completed) SK (Completed) CZ (Completed) SI (Completed) ES (Completed) DE (Completed) LV (Completed) PL (Completed) NL (Completed) Outside EU/EEA NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003027-30 Sponsor Protocol Number: IIBSP-ALB-2017-72 Start Date*: 2017-11-27
    Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau
    Full Title: Influence of albumin on the development of acute renal dysfunction associated with cardiac surgery under extracorporeal circulation
    Medical condition: Renal function
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 00:29:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA